academic

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Account opportunity

Not established

Relationship

Active signals

Trials as sponsor

Why this account matters

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

New trial — KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

New trialNCT06411691

53/100

Opportunity

Commercial fit11/25

Clinical timing20/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency1/5

New phase 1 trial NCT06411691 posted by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: "KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 39 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

New trial — Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

New trialNCT05013216

48/100

Opportunity

Commercial fit6/25

Clinical timing20/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency1/5

New phase 1 trial NCT05013216 posted by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: "Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 70 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

Trial	Phase	Testing language
NCT06411691 KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer	phase 1	—
NCT05013216 Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer	phase 1	mol. elig.